Business · 12/03/2014Updated: 10/17/2026 · 1 min read
FDA Awards Priority Review Voucher to BioMarin Pharmaceutical for Rare Pediatric Disease Product VIMIZIM
Summary
The FDA has issued a priority review voucher to BioMarin Pharmaceutical, Inc. for its rare pediatric disease product VIMIZIM, following a review of the product's eligibility under the FD&C Act and FDASIA.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →